Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Cytomegalovirus Infections 4Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Multi-centric Castleman's Disease 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Solid Tumor, Adult 1Sezary Syndrome 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

ziprasidone 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Valganciclovir 1Tranexamic Acid 1Tobramycin 1Spironolactone 1Sevelamer 1Rocuronium 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1Methylprednisolone 1Matrix-M 1Lurasidone Hydrochloride 1Labetalol 1Haloperidol 1Gene-Eden-VIR 1Fosfomycin 1Clozapine 1Ciprofloxacin 1Cidofovir 1Cefepime 1Bosentan 1Aminocaproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Herpes Simplex × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡